Fundraising Fox

Genomenon

Ann Arbor, US · Founded 2014 · Delaware corporation · 139 employees on LinkedIn · 8 known investors

Genomenon uses AI to read biomedical literature and expert scientists to curate variant- and patient-level genomic evidence, delivering regulatory-grade real-world evidence. Its products, including Mastermind and CKB, serve drug development teams and clinical genetic testing labs for variant interpretation and drug program decisions.

AI & Machine LearningBiotechDigital Health

Founders & leadership

Genomenon was founded in 2014 by Mark Kiel.

MKMark Kiel
Mark KielFounder
ES
Eli SalembierExecutive
SGSam Globus
Sam GlobusinExecutive
DS
Dr. Sam GlobusChief Operating Officer
MK
Michael KleinNamed on SEC filing
DG
David GregorkaNamed on SEC filing
BG
Brian GroarkinNamed on SEC filing

Board

PG
Patricia GlazaBoard director
MGMichael Gross
Michael GrossinBoard MemberManaging Partner at Beringea
SS
Sonya SepahbanBoard director

Investors · 8

BeringeaLondon · $3M – $10M
Green Park & Golf VenturesDallas · $500K – $2M
ID VenturesDetroit · $50K – $250K
Invest MichiganNorthville · $100K – $250K
IrishAngelsSan Francisco · $250K – $350K
Marram VenturesSaugatuck · $3M
Michigan RiseEast Lansing · $50K – $150K
Spring Mountain CapitalreportedNew York

Reported raises · per SEC filings

Form D private placements

$34.8M disclosed across 5 rounds · 2015–2026

▶$6MraisedJul 2026 · 30 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael KleinExecutive Officer, Director
  • Mark KielExecutive Officer, Director
  • Patricia GlazaDirector
  • David GregorkaDirector
  • Michael GrossDirector
  • Brian GroarkExecutive Officer
  • Sam GlobusExecutive Officer
Offering amount
$10M
Amount sold
$6M
First sale
Jul 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.5MraisedMay 2024 · 30 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark KielExecutive Officer, Director
  • Patricia GlazaDirector
  • Michael KleinExecutive Officer, Director
  • David GregorkaDirector
  • Michael GrossDirector
  • Sam GlobusExecutive Officer
  • Sean KearneyExecutive Officer
Offering amount
$6M
Amount sold
$5.5M
First sale
May 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20MraisedMar 2022 · 23 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael KleinExecutive Officer, Director
  • David GregorkaDirector
  • Patricia GlazaDirector
  • Michael GrossDirector
  • Mark KielExecutive Officer, Director
Offering amount
$20M
Amount sold
$20M
First sale
Feb 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.9MraisedMay 2020 · 36 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark KielExecutive Officer, Director
  • Michael KleinExecutive Officer, Director
  • David GregorkaDirector
  • Steve SchwartzExecutive Officer
  • Patricia GlazaDirector
  • Charles MoretDirector
Offering amount
$3M
Amount sold
$2.9M
First sale
May 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$446KraisedAug 2015 · 11 investors · Computers
Rule 506(b)
Officers, directors & promoters on the filing
  • Eli SalembierExecutive Officer, Director
  • Mark KielExecutive Officer, Director
  • Sonya SepahbanDirector
Offering amount
$1M
Amount sold
$446K
First sale
Aug 2015
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Abcam342 shared keywordsSupplier of protein research tools to life scientists. Publicly listed on the LSE following an IPO.

Companies competing with Genomenon for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Invest Michigan | Pressinvestmichigan.org · Nov 2025University of Michigan Startup, Genomenon, Raises $20M Series B Financing - UM - Innovation Partnershipsinnovationpartnerships.umich.edu · Jul 2022Genomenon Closes $20M Series B Funding Round | GenomeWebgenomeweb.com · Mar 2022Genomenon Raises $20M Series B Financing, Launching a New Era in AI-Powered Genomic Dataprweb.com · Mar 2022Genomenon Raises $2.5M in Equity Financing Round | GenomeWebgenomeweb.com · Jan 2019Genomenon Raises $940,000 in Seed Venture Funding Round | GenomeWebgenomeweb.com · Jan 2016

Frequently asked questions

What does Genomenon do?
Genomenon uses AI to read biomedical literature and expert scientists to curate variant- and patient-level genomic evidence, delivering regulatory-grade real-world evidence. Its products, including Mastermind and CKB, serve drug development teams and clinical genetic testing labs for variant interpretation and drug program decisions.
Who founded Genomenon?
Genomenon was founded by Mark Kiel in 2014.
Who are Genomenon's investors?
Genomenon's investors include Beringea, Green Park & Golf Ventures, ID Ventures, Invest Michigan, IrishAngels, Marram Ventures, Michigan Rise, Spring Mountain Capital.
How much funding has Genomenon raised?
Genomenon has disclosed $34.8M raised across 5 rounds.
Where is Genomenon headquartered?
Genomenon is headquartered in Ann Arbor, US.